FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174403800> ?p ?o ?g. }

• W3174403800 abstract "Ovarian cancer is the most lethal type of gynecological cancer. Due to its high heterogeneity and complicated pathological mechanisms, the 5‑year survival rate of patients with ovarian cancer is <40%. Tumor cytoreductive surgery and systemic chemotherapy of platinum combined with paclitaxel are currently considered the gold standard for the treatment of ovarian cancer, and chemotherapy resistance has become a key constraint in improving the cure rate of ovarian cancer. Therefore, it is important to identify novel treatment methods and strategies for ovarian cancer. Targeted drugs can not only be used in combination with chemotherapy, but also act as maintenance therapy to promote patient survival time. PARP inhibitor is a novel type of ovarian cancer treatment targeted drug, which can induce an anticancer effect by inhibiting DNA damage and repair of ovarian cancer cells. The present study investigated the different effects of olaparib, cisplatin and paclitaxel in several dosages by single use and combinations on the proliferation of different human ovarian cancer cell lines, in order to verify the synergistic effects of the combinations of the three anticancer agents in pairs. The proliferation inhibitory rate of the cell lines was determined using a Cell Counting Kit‑8 assay, while the combination index (CI) value of the combination of three agents in pairs was analyzed using Compusyn software. The proliferation was observed using a crystal violet assay, and the apoptosis ratio was measured via flow cytometry. The results of the present study revealed that the combination of cisplatin with olaparib group had a higher inhibition effect than each single group and had a higher dose‑reduction index of >1 than the other two combinations at all concentrations in A2780 and OVCAR‑3 cell lines. The difference in proliferation inhibition and induced apoptosis rate of A2780 cell lines was significant in the combination of cisplatin with olaparib group and the control group (P<0.01) at 0.25x IC₅₀. For the OVCAR‑3 cell line, the difference was also significant between two groups (P<0.05). The CI values in the A2780 cell line revealed significant differences between the low‑dose group (0.0625x, 0.125x and 0.25x IC₅₀) and the high‑dose group (0.5x, 1.0x and 2.0x IC₅₀) for the group that received the combination of cisplatin with olaparib (P<0.05). The present study highlighted that the group receiving a combination of cisplatin with olaparib exhibited the most significant synergistic effects among the three combinations, particularly at low doses." @default.
• W3174403800 created "2021-07-05" @default.
• W3174403800 creator A5008737716 @default.
• W3174403800 creator A5010220134 @default.
• W3174403800 creator A5013095342 @default.
• W3174403800 creator A5064351460 @default.
• W3174403800 creator A5067290436 @default.
• W3174403800 creator A5090889617 @default.
• W3174403800 date "2021-07-01" @default.
• W3174403800 modified "2023-10-10" @default.
• W3174403800 title "Combination treatment with cisplatin, paclitaxel and olaparib has synergistic and dose reduction potential in ovarian cancer cells" @default.
• W3174403800 cites W1975307022 @default.
• W3174403800 cites W1975426150 @default.
• W3174403800 cites W1984087886 @default.
• W3174403800 cites W1988775531 @default.
• W3174403800 cites W1999659306 @default.
• W3174403800 cites W2006579730 @default.
• W3174403800 cites W2022293423 @default.
• W3174403800 cites W2023881529 @default.
• W3174403800 cites W2033816200 @default.
• W3174403800 cites W2048305487 @default.
• W3174403800 cites W2058493425 @default.
• W3174403800 cites W2072528578 @default.
• W3174403800 cites W2082506448 @default.
• W3174403800 cites W2088312612 @default.
• W3174403800 cites W2098681754 @default.
• W3174403800 cites W2117639046 @default.
• W3174403800 cites W2119478570 @default.
• W3174403800 cites W2130078242 @default.
• W3174403800 cites W2145409983 @default.
• W3174403800 cites W2169961966 @default.
• W3174403800 cites W2179105349 @default.
• W3174403800 cites W2181166720 @default.
• W3174403800 cites W2279794621 @default.
• W3174403800 cites W2332482462 @default.
• W3174403800 cites W2412945422 @default.
• W3174403800 cites W2558710021 @default.
• W3174403800 cites W2562297554 @default.
• W3174403800 cites W2626100359 @default.
• W3174403800 doi "https://doi.org/10.3892/etm.2021.10367" @default.
• W3174403800 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8290430" @default.
• W3174403800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34335884" @default.
• W3174403800 hasPublicationYear "2021" @default.
• W3174403800 type Work @default.
• W3174403800 sameAs 3174403800 @default.
• W3174403800 citedByCount "6" @default.
• W3174403800 countsByYear W31744038002022 @default.
• W3174403800 countsByYear W31744038002023 @default.
• W3174403800 crossrefType "journal-article" @default.
• W3174403800 hasAuthorship W3174403800A5008737716 @default.
• W3174403800 hasAuthorship W3174403800A5010220134 @default.
• W3174403800 hasAuthorship W3174403800A5013095342 @default.
• W3174403800 hasAuthorship W3174403800A5064351460 @default.
• W3174403800 hasAuthorship W3174403800A5067290436 @default.
• W3174403800 hasAuthorship W3174403800A5090889617 @default.
• W3174403800 hasBestOaLocation W31744038001 @default.
• W3174403800 hasConcept C104317684 @default.
• W3174403800 hasConcept C121608353 @default.
• W3174403800 hasConcept C126322002 @default.
• W3174403800 hasConcept C143998085 @default.
• W3174403800 hasConcept C182979987 @default.
• W3174403800 hasConcept C2776694085 @default.
• W3174403800 hasConcept C2777292972 @default.
• W3174403800 hasConcept C2778239845 @default.
• W3174403800 hasConcept C2779962180 @default.
• W3174403800 hasConcept C2780427987 @default.
• W3174403800 hasConcept C502942594 @default.
• W3174403800 hasConcept C55493867 @default.
• W3174403800 hasConcept C71924100 @default.
• W3174403800 hasConcept C82381507 @default.
• W3174403800 hasConcept C86803240 @default.
• W3174403800 hasConcept C96232424 @default.
• W3174403800 hasConcept C98274493 @default.
• W3174403800 hasConceptScore W3174403800C104317684 @default.
• W3174403800 hasConceptScore W3174403800C121608353 @default.
• W3174403800 hasConceptScore W3174403800C126322002 @default.
• W3174403800 hasConceptScore W3174403800C143998085 @default.
• W3174403800 hasConceptScore W3174403800C182979987 @default.
• W3174403800 hasConceptScore W3174403800C2776694085 @default.
• W3174403800 hasConceptScore W3174403800C2777292972 @default.
• W3174403800 hasConceptScore W3174403800C2778239845 @default.
• W3174403800 hasConceptScore W3174403800C2779962180 @default.
• W3174403800 hasConceptScore W3174403800C2780427987 @default.
• W3174403800 hasConceptScore W3174403800C502942594 @default.
• W3174403800 hasConceptScore W3174403800C55493867 @default.
• W3174403800 hasConceptScore W3174403800C71924100 @default.
• W3174403800 hasConceptScore W3174403800C82381507 @default.
• W3174403800 hasConceptScore W3174403800C86803240 @default.
• W3174403800 hasConceptScore W3174403800C96232424 @default.
• W3174403800 hasConceptScore W3174403800C98274493 @default.
• W3174403800 hasIssue "3" @default.
• W3174403800 hasLocation W31744038001 @default.
• W3174403800 hasLocation W31744038002 @default.
• W3174403800 hasOpenAccess W3174403800 @default.
• W3174403800 hasPrimaryLocation W31744038001 @default.
• W3174403800 hasRelatedWork W1970921743 @default.
• W3174403800 hasRelatedWork W2085978374 @default.
• W3174403800 hasRelatedWork W2320097775 @default.
• W3174403800 hasRelatedWork W2328421677 @default.
• W3174403800 hasRelatedWork W2489762468 @default.

• next